Tirzepatide Compared With Lifestyle Changes for Obesity in Bangladesh
Compares tirzepatide with diet and exercise in adults with obesity, with or without diabetes.
Plain-language title generated from the registry record
Registry title: Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
Key facts
- Where
- Comilla, Dhaka, and Rajshahi, BangladeshSee the 3 sites
Where in Bangladesh
- Trauma Centre, Cumilla.Comilla, BangladeshNo longer taking part
- Dhaka Medical College Hospital, DhakaDhaka, BangladeshNo longer taking part
- Rajshahi Medical College Hospital, RajshahiRajshahi, BangladeshNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dr. Md. Alimur Reza
- Trial code
- NCT07099742
- Record updated
- 7 October 2026
- Original description
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).Read full original descriptionShow less
A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).
The study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg/m² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.
Inclusion: Adult patients of both sexes, aged ≥18 years; Body mass index (BMI) ≥25 kg/m²; Naïve to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy; Self-reported stable body weight (change ≤5 kg) over the past 3 months.
Exclusion: Prior or planned surgical treatment for obesity; Use of weight-loss products (including prescription medications, over-the-counter drugs, or herbal preparations) within 3 months prior to screening; Diagnosis of diabetes other than Type 2 Diabetes Mellitus; History of chronic or acute pancreatitis; Presence of acute medical conditions, including acute hepatitis, myocardial infarction, stroke, heart failure, febrile illness, or acute diarrheal disease; Evidence of significant, uncontrolled endocrine disorders (e.g., Cushing's syndrome, thyroid disorders, adrenal insufficiency, congenital adrenal hyperplasia); History or presence of malignancy; Active gallbladder disease; Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential, not using adequate contraceptive methods.